Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Innovating Sickle Cell Disease Treatment: From Non-Canonical Signaling and Immune Activation to Personalized Targeted Therapies

Obiettivo

This project addresses the unmet clinical needs of sickle cell disease (SCD), the most common monogenic disorder worldwide, characterized by chronic inflammation, multi-organ involvement, and severely impaired erythropoiesis. SCD pathophysiology is driven by hemoglobin S polymerization, leading to vaso-occlusion (VOC) and acute chest syndrome (ACS), oxidative stress, and activation of innate immunity. Our multidisciplinary approach combines patient-driven biomarker studies, mechanistic investigations in human and mouse models, and exploration of innovative therapies. Preliminary data reveal that chronic bone marrow inflammation impairs hematopoietic stem/progenitor cell functions, alters erythroid differentiation, and increases myeloid bias, all contributing to poor transplant and gene therapy outcomes. Novel research in our group highlights the role of non-canonical histidine phosphorylation (NME1/NME2) in regulating BCL11A activity for fetal hemoglobin synthesis, and demonstrates that pharmacological targeting of these kinases safely induces HbF in human progenitors. We also uncover critical roles for mast cells and basophils, showing that their activation drives pain, vaso-occlusion, and neuroinflammation. Candidate drugs, including masitinib, luspatercept, and anti-inflammatory agents, are tested for their ability to improve hematopoiesis, reduce acute and chronic complications, and modulate the bone marrow niche. By integrating high-throughput sequencing, multi-omic profiling, and advanced mouse genetics, this project aims to identify new biomarkers and therapeutic strategies to personalize SCD care, improve gene therapy success, and rapidly translate findings from bench to bedside, offering hope for patients globally.

Campo scientifico (EuroSciVoc)

Questo progetto non è ancora stato classificato con EuroSciVoc.
Suggerisci i campi scientifici che ritieni più rilevanti e aiutaci a migliorare il nostro servizio di classificazione.

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC - HORIZON ERC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2025-ADG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

UNIVERSITE PARIS CITE
Contributo netto dell'UE
€ 1 460 375,00
Indirizzo
85 BD SAINT GERMAIN
75006 Paris
Francia
Regione
Ile-de-France Ile-de-France Paris
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Beneficiari (2)